Enhanced Natural Killers with CISH and B2M Gene Knockouts Reveal Increased Cytotoxicity in Glioblastoma Primary Cultures
In an experimental study using the CRISPR/Cas9 system, “enhanced” NK cell lines with knockout of CISH , the gene for the CIS protein (a negative regulator of NK cytotoxicity), as well as two lines with a knocked-out β2-microglobulin gene, which provides membrane exposure of MHC class I, were obtaine...
Saved in:
Published in: | Molecular biology (New York) Vol. 56; no. 5; pp. 770 - 779 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Moscow
Pleiades Publishing
01-10-2022
Springer Nature B.V |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | In an experimental study using the CRISPR/Cas9 system, “enhanced” NK cell lines with knockout of
CISH
, the gene for the CIS protein (a negative regulator of NK cytotoxicity), as well as two lines with a knocked-out β2-microglobulin gene, which provides membrane exposure of MHC class I, were obtained from two parental lines of human natural killers (YT wild type and YT-VAV1
+
overexpressing the VAV1 cytotoxicity enhancing protein). The knockout efficiency was determined by real-time PCR as well as by flow cytometry with specific antibodies. The resulting
CISH
–/–
or
B2M
–/–
knockout lines were tested for cytotoxicity in primary monolayer cultures of human glioblastoma multiforme. The cytotoxicity of the lines was assessed using a cell analyzer that records the cell index based on cell impedance. YT-CISH
–/–
has been shown to be significantly more effective than wild-type YT in eliminating primary glioblastoma cells in an in vitro cell monolayer experiment. The cytotoxicity of the YT-VAV1
+
-CISH
–/–
and YT-VAV1
+
B2M
–/–
lines against glioblastoma cells was the highest, but overall, it did not significantly differ from the initially increased cytotoxicity of the YT-VAV1
+
line. The lines of NK-like cells obtained may serve as a prototype for the creation of “enhanced” allogeneic and autologous NK- and CAR-NK cells for the immunotherapy of glioblastoma multiforme. |
---|---|
ISSN: | 0026-8933 1608-3245 |
DOI: | 10.1134/S0026893322050156 |